ABSTRACT
Objective To investigate the efficacy and safety of interventional sclerotherapy for cystic lymphatic malformation(cLM).Methods A total of 92 cases of cLM were enrolled in this study.Forty-seven cases were macrocystic lymphatic malformation(LM),32 cases were mixed LM,and 13 cases were microcystic LM.At the first treatment,56 cases with clear or light yellow cystic fluid were defined as non-bleeding group;Thirty-six cases with cloudy or dark red cystic fluid were defined as bleeding group.Sclero-therapy was performed under the guidance of fluoroscopy or ultrasonic(US),followed by an outpatient or a telephone follow-up at least 3 months after operation.Results Ninety-two patients received 140 times of interventional sclerotherapy,with an average of 1.53 times.The overall cure rate was 56.5%and the overall effective rate was 95.7%.The results of subgroup analysis showed that the overall effective rate of macrocystic and mixed LM was higher than that of microcystic LM,while the overall effective rate of macrocystic and mixed LM had no statistical difference.The cure rate of macrocystic LM was higher than that of mixed and microcystic LM,but there was no significant difference between mixed and microcystic LM.Besides,there were no statistical differences in the overall effective rate and the cure rate between the bleeding group and the non-bleeding group.Conclusion Interventional sclerotherapy is a safe and effective treatment for cLM patients.The efficacy of interventional sclerotherapy is not affected by the presence or absence of intracapsular hemorrhage during the first treatment.
ABSTRACT
Objective Hypothermic machine perfusion may improve the outcome after transplantation of kidney donated after citizen's death (DCD),but few powered prospective studies have been reported,especially in China.The aim is to compare hypothermic machine perfusion (HMP) with simple cold storage (SCS) in Chinese DCD kidney transplantation,which can offer an optimal method for graft storage with better graft function and survival.Methods 54 kidney pairs from DCD donors were included in this controlled trial in one single center from December 2015 to March 2017.Every two kidneys from each DCD donor wavs randomly assigned to HMP and SCS group.One-year recipient and graft survival rate and endpoints containing the incidence of DGF,the duration of DGF,creatinine reduction ratio (CRR),estimated glomerular filtration rate (Egfr),primary non-function (PNF),acute rejection (AR),toxicity of the immunosuppressive drugs,nosocomial infections and the length of hospital stay were compared between HMP and SCS group.Results One-year recipient survival rate was 98.15 ％ and 96.23％ after DCD transplant in HMP and SCS group,and one-year graft survival rate was 90.74％ and 88.68％,respectively.DGF incidence was 9.62％ in total DCD kidney transplant,8.00％ in HMP group and 11.11％ in SCS group,which was no difference in two groups.22 DCD was from expanded criteria donor (ECD) donation,DGF happened in 15.91％ ECD kidney transplant.However,HMP reduced the incidence of DGF from 27.27％ to 4.55％ after ECD kidney transplant,which was significantly different (x2 =4.247,P =0.039).HMP group acquired significantly lower creatinine level (130.95 ± 46.60) μmol/L than SCS group (181.64 ± 72.94) μmol/L on day 14 after ECD transplant (t =-2.686,P =0.011).Conclusion There was a higher recipient and graft survival rate after DCD and ECD kidney transplant,which would be an effective method to expand donor pool for kidney transplant.HMP was not associated with lower DGF rate in DCD kidney transplant and more rapid recovery in early graft function.However,HMP preservation not only made renal function recover more rapidly but reduced the risk of DGF after ECD kidney transplant.